# US 2022/0032267 A1 · Use Of A Hemocompatible Porous Polymer Bead Sorbent For Removal Of Endotoxemia-Inducing Molecules

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0032267 A1
- Document ID: US20220032267A1
- Status: Published application
- Kind: A1
- Application number: 17/372,985
- Filed: 2021-07-12
- Published: 2022-02-03
- Earliest claimed: 2016-05-26
- Assignees: CytoSorbents Corporation
- Applicants: CytoSorbents Corporation
- Inventors: Tamaz Guliashvili; Thomas Golobish; Maryann Gruda; Pamela O'Sullivan; Andrew Scheirer; Vincent Capponi; Phillip Chan; Wei-Tai Young
- Web page: https://patentgrep.com/patent/US20220032267A1

## CPC

- B01J 20/261: {obtained by reactions only involving carbon to carbon unsaturated bonds (macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds per se C08F)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/745: Polymers of hydrocarbons
- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- B01D 15/34: Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
- B01J 20/262: {obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. obtained by polycondensation (macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds per se C08G)}
- B01J 20/267: {Cross-linked polymers}
- B01J 20/28069: {Pore volume, e.g. total pore volume, mesopore volume, micropore volume}
- B01J 20/28078: {Pore diameter}
- B01J 20/2808: {being less than 2 nm, i.e. micropores or nanopores}
- B01J 20/28083: {being in the range 2-50 nm, i.e. mesopores}
- B01J 20/28085: {being more than 50 nm, i.e. macropores}
- B01J 20/3208: {Polymeric carriers, supports or substrates}
- B01J 20/3231: {characterised by the coating or impregnating layer}
- B01J 20/327: {Polymers obtained by reactions involving only carbon to carbon unsaturated bonds}
- B01J 20/3272: {Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds}
- B01J 20/3274: {Proteins, nucleic acids, polysaccharides, antibodies or antigens}
- B01J 20/3289: {Coatings involving more than one layer of same or different nature}
- B01D 15/125: {Pre-filtration}
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

The invention concerns biocompatible polymer systems comprising at least one polymer with a plurality of pores, said polymer comprising either polyol or zwitterionic groups designed to adsorb endotoxins and other inflammatory mediator molecules. The inventions are in the field of porous polymeric sorbents, also in the field of broadly reducing endotoxins in blood and blood products that can cause endotoxemia, additionally, in the field of broadly removing endotoxins by perfusion or hemoperfusion.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A method of adsorbing toxins and inflammatory mediators comprising contacting physiologic fluid with a polymer system comprising either polyol or zwitterionic functionality;
said polymer system has the form of a solid support having a polymer coating comprising poly(diethylaminoethyl methacrylate), poly(dimethylaminoethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxyethyl methacrylate), poly(hydroxypropyl acrylate), poly (hydroxypropyl methacrylate), poly(N-vinylpyrrolidone), poly(vinyl alcohol), salts of poly(acrylic acid), salts of poly(methacrylic) acid, or mixtures thereof.

### Claim 42 (depends on 41)

The method of claim 41 wherein the said toxins and inflammatory mediators have a molecular weight of from less than 0.5 kDa to 1,000 kDa.

### Claim 43 (depends on 41)

The method of claim 41 wherein the said toxins and inflammatory mediators have a molecular weight of from less than 0.5 kDa to 60 kDa.

### Claim 44 (depends on 41)

The method of claim 41 wherein the toxins and inflammatory mediators comprise one or more of cytokines, pathogen-associated molecular pattern molecules (PAMPs), damage-associated molecular pattern molecules (DAMPs), superantigens, monokines, chemokines, interferons, proteases, enzymes, peptides including bradykinin, soluble CD40 ligand, bioactive lipids, oxidized lipids, cell-free hemoglobin, cell-free myoglobin, growth factors, glycoproteins, prions, toxins, bacterial and viral toxins, drugs, vasoactive substances, foreign antigens, and antibodies.

### Claim 45 (depends on 41)

The method of claim 41 wherein the polymer system is also capable of adsorbing one or more of gram-negative bacteria, gram-negative bacteria fragments, and gram-negative bacterial components.

### Claim 46 (depends on 41)

The method of claim 41 wherein the polymer system is also capable of adsorbing one or more of gram-positive bacteria, gram-positive bacteria fragments, and gram-positive bacterial components.

### Claim 47 (depends on 41)

The method of claim 41 wherein the polymer system is in the form of a solid support selected from beads, fibers, monolithic columns, film, membranes, or semi-permeable membranes.

### Claim 48 (depends on 41)

The method of claim 41 wherein the polymer system comprises a plurality of pores and a total volume of pore sizes in the range of from 10 Å to 40,000 Å greater than 0.1 cc/g and less than 5.0 cc/g dry polymer.

### Claim 49 (depends on 41)

The method of claim 41, wherein the polymer system is nonporous.

### Claim 50 (depends on 41)

The method of claim 41 wherein the polymer system further comprises a hypercrosslinked polymer.

### Claim 51 (depends on 41)

The method of claim 41 wherein the polymer system further comprises either (i) heparin or (ii) a heparin mimicking polymer.

### Claim 52 (depends on 41)

The method of claim 41, comprising passing the physiologic fluid one or more times through an extracorporeal circuit comprising a device comprising the polymer system.
